VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 75 filers reported holding VIRIDIAN THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $43,527,961 | -23.1% | 3,345,731 | +3.4% | 0.00% | 0.0% |
| Q1 2024 | $56,632,226 | -13.4% | 3,234,279 | +7.8% | 0.00% | 0.0% |
| Q4 2023 | $65,360,647 | +74.1% | 3,000,948 | +22.6% | 0.00% | 0.0% |
| Q3 2023 | $37,552,550 | -39.2% | 2,448,015 | -5.7% | 0.00% | 0.0% |
| Q2 2023 | $61,774,161 | +14.0% | 2,596,644 | +21.9% | 0.00% | 0.0% |
| Q1 2023 | $54,193,128 | -12.3% | 2,130,233 | +0.7% | 0.00% | -50.0% |
| Q4 2022 | $61,778,974 | +62.2% | 2,114,994 | +13.9% | 0.00% | +100.0% |
| Q3 2022 | $38,083,000 | +133.3% | 1,856,800 | +31.6% | 0.00% | – |
| Q2 2022 | $16,324,000 | -6.1% | 1,410,902 | +50.0% | 0.00% | – |
| Q1 2022 | $17,391,000 | -5.0% | 940,577 | +1.6% | 0.00% | – |
| Q4 2021 | $18,301,000 | +140.8% | 925,676 | +100.4% | 0.00% | – |
| Q3 2021 | $7,599,000 | +17.3% | 461,912 | +30.5% | 0.00% | – |
| Q2 2021 | $6,476,000 | +130.1% | 354,066 | +110.1% | 0.00% | – |
| Q1 2021 | $2,815,000 | – | 168,518 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,882,671 | $50,513,550 | 3.22% |
| Rosalind Advisors, Inc. | 300,000 | $3,903,000 | 3.00% |
| Fairmount Funds Management LLC | 1,845,813 | $24,014,027 | 2.71% |
| Ghost Tree Capital, LLC | 587,708 | $7,646,081 | 2.39% |
| COMMODORE CAPITAL LP | 2,528,032 | $32,889,696 | 2.24% |
| ACUTA CAPITAL PARTNERS, LLC | 199,433 | $2,594,623 | 2.18% |
| 5AM Venture Management, LLC | 736,595 | $9,583,101 | 2.14% |
| Vivo Capital, LLC | 1,678,207 | $21,833,473 | 2.02% |
| TANG CAPITAL MANAGEMENT LLC | 1,392,925 | $18,121,954 | 1.85% |
| Kynam Capital Management, LP | 1,750,000 | $22,767,500 | 1.76% |